IOPAMIDOL INJECTION

Iopamidol Injection, identified by NSN 6505-01-657-0664 and NDC 00270-1316-35, is a non-intrathecal contrast agent supplied in ten 100 mL single-dose bottles per package, with a shelf life of 24 months that is non-extendable and classified as a Type I Code M item. The product must be stored at 20 to 25°C (68 to 77°F) and protected from light, in compliance with USP standards. Packaging and marking must adhere strictly to Medical Marking Standard No. 1, which replaces all references to MIL-STD-129, and each unit must be sealed in a container that prevents damage or breakage, with outer shipping containers ensuring safe, cost-effective delivery via common carrier to the destination. The item is subject to Federal Acquisition Regulation requirements for medical acquisitions, including commercial packaging standards, and is classified under hazardous materials handling protocols due to its nature. Delivery is required FOB destination within five days of contract award, with zero tolerance for quantity variance, and inspection and acceptance occur at the delivery point. The contract, issued under solicitation SPE2DP-26-T-4236 by the Department of Defense’s Medical Supply Chain Pharmaceutical FSA, is for one package with delivery required by July 24, 2026, and is managed by Bracco Diagnostics Inc. with technical and quality requirements referenced from the DLA Master List. All logistics, labeling, and compliance must conform to DLA specifications, and the point of contact for inquiries is Timothy McCauley at DLA.